Isomorphic Labs, a spinout from DeepMind, has successfully raised $2.1 billion in its second funding round, aided by prominent investors such as Thrive Capital, Alphabet, and several sovereign wealth funds. This significant investment aims to further the company’s goal of developing AI-designed drugs, with ongoing programs targeting cardiovascular disease, cancer, and immunology. Notably, Isomorphic is advancing its first computationally designed therapeutics into human clinical trials, leveraging cutting-edge AI technology recognized by a Nobel Prize. Additionally, the company collaborates with major pharmaceutical firms such as Eli Lilly, Novartis, and Johnson & Johnson to enhance its drug development capabilities.

Alphabet Inc.: Alphabet Inc. is the parent company of Google and DeepMind, driving AI innovations in areas ranging from search and cloud computing to life sciences and biotechnology. It owns Isomorphic Labs, the DeepMind spinout focused on AI drug design.21 Alphabet participated as an investor in Isomorphic Labs’ recent funding round to support AI applications in drug discovery.
Thrive Capital: Thrive Capital is a venture capital firm that invests in technology, media, and AI-driven companies, with a portfolio including early stakes in platforms like Instagram, Spotify, and OpenAI. It recently announced Thrive Eternal, a permanent capital vehicle for long-term holdings in cultural and tech assets.13 In this news, Thrive Capital led the funding round for Isomorphic Labs to propel AI drug design forward.
Isomorphic Labs: Isomorphic Labs is a UK-based biotechnology company spun out from Alphabet’s Google DeepMind that specializes in AI-powered drug discovery, leveraging models like AlphaFold and IsoDDE to predict protein structures and design novel therapeutics for oncology, immunology, and other areas. It has partnerships with major pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson to advance multiple drug programs toward clinical trials.206 In the news, Isomorphic Labs raised a major funding round led by Thrive Capital, with participation from Alphabet and sovereign wealth funds, to accelerate development of artificial intelligence-designed drugs.

Drug Programs: Isomorphic Labs runs multiple live drug development programs in cardiovascular disease, cancer, and immunology using AI models.
Clinical Advancement: The company is advancing its first computationally designed therapeutics into human clinical trials using Nobel Prize-winning AI technology.
Pharma Collaborations: Isomorphic Labs partners with Eli Lilly, Novartis, and Johnson & Johnson for AI-designed drug initiatives.